Induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin in Japanese patients with HER2-negative metastatic breast cancer: a multicenter, collaborative, open-label, phase II clinical study for the SBCCSG 35 investigators

BACKGROUND: To examine the efficacy and safety of induction therapy with paclitaxel and bevacizumab followed by switch maintenance therapy with eribulin (ISMT) in Japanese patients with HER2-negative metastatic breast cancer (MBC). METHODS: Patients, who had previously undergone a maximum of 2 regim...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Kenichi, Ninomiya, Jun, Saito, Tsuyoshi, Kimizuka, Kei, Kurosumi, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011527/
https://www.ncbi.nlm.nih.gov/pubmed/29925345
http://dx.doi.org/10.1186/s12885-018-4556-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6011527/
https://www.ncbi.nlm.nih.gov/pubmed/29925345
http://dx.doi.org/10.1186/s12885-018-4556-6

Ejemplares similares